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background:  Newer-generation drug-eluting stent (DES) have shown to the improved safety and efficacy compared with first-generation 
DES. The treatment of in-stent restenosis (ISR) lesions is one of the unsolved issues even in the DES era and it remains unclear whether 
clinical outcome after newer-generation DES implantation for ISR lesion was similar to that for non-ISR lesion. Our aim was to assess 
the clinical outcomes after the Nobori biolimus-eluting stent (BES) and Xience everolimus-eluting stent (EES) implantation for ISR lesion 
compared with that for non-ISR lesion.
methods:  A total of 2497 patients with 3410 lesions undergoing BES and EES implantation between February 2010 and July 2012 were 
analyzed. We assessed the 2-year cumulative incidences of major adverse cardiac events (MACE), defined as a composite of cardiac 
death, non-fatal myocardial infarction, definite stent thrombosis, and clinically driven target lesion revascularization (TLR) between the ISR 
and non-ISR groups.
results:  Of 2497 patients with 3410 lesions, 366 patients had 388 ISR lesions treated with BES (183 patients with 192 lesions) or EES 
(183 patients with 196 lesions). At 2-year, the cumulative incidence of MACE was significantly higher in the ISR group than in the non-
ISR group (12.3% vs. 8.0%, p=0.012), mainly driven by the higher rate of TLR (9.3% vs. 5.1%, p=0.003). The cumulative incidences of 
cardiac death, myocardial infarction, and stent thrombosis were not different between the ISR and non-ISR groups (3.6% vs. 2.7%, p=0.42; 
1.9% vs. 1.2%, p=0.27; 1.4% vs. 0.7%, p=0.16, respectively). There were no significant differences in the rates of MACE, cardiac death, 
myocardial infarction, stent thrombosis and clinically driven TLR between the BES and EES. ISR lesion, hemodialysis, diabetes mellitus 
were predictors of MACE.
Conclusion:  Two-year clinical outcome after BES and EES implantation for ISR lesions was associated with higher rate of clinically driven 
TLR compared with that for non-ISR lesions.
